EA201790142A1 - Лечение лейкоза ингибиторами гистондеацетилазы - Google Patents

Лечение лейкоза ингибиторами гистондеацетилазы

Info

Publication number
EA201790142A1
EA201790142A1 EA201790142A EA201790142A EA201790142A1 EA 201790142 A1 EA201790142 A1 EA 201790142A1 EA 201790142 A EA201790142 A EA 201790142A EA 201790142 A EA201790142 A EA 201790142A EA 201790142 A1 EA201790142 A1 EA 201790142A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
treatment
leukemia
need
hdac inhibitor
Prior art date
Application number
EA201790142A
Other languages
English (en)
Russian (ru)
Inventor
Саймон С. Джонс
Чэнинь Минь
Минь Ян
Дэвид Ли Тейменг
Original Assignee
Эситайлон Фармасьютикалз, Инк.
Дэвид Ли Тейменг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эситайлон Фармасьютикалз, Инк., Дэвид Ли Тейменг filed Critical Эситайлон Фармасьютикалз, Инк.
Publication of EA201790142A1 publication Critical patent/EA201790142A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201790142A 2014-07-07 2015-07-06 Лечение лейкоза ингибиторами гистондеацетилазы EA201790142A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462021473P 2014-07-07 2014-07-07
US201462061233P 2014-10-08 2014-10-08
US201562147218P 2015-04-14 2015-04-14
PCT/US2015/039225 WO2016007423A1 (en) 2014-07-07 2015-07-06 Treatment of leukemia with histone deacetylase inhibitors

Publications (1)

Publication Number Publication Date
EA201790142A1 true EA201790142A1 (ru) 2017-07-31

Family

ID=55064739

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790142A EA201790142A1 (ru) 2014-07-07 2015-07-06 Лечение лейкоза ингибиторами гистондеацетилазы

Country Status (13)

Country Link
US (1) US9833466B2 (enExample)
EP (1) EP3166603B1 (enExample)
JP (1) JP6952602B2 (enExample)
KR (1) KR20170044097A (enExample)
CN (1) CN107205988A (enExample)
AU (1) AU2015288060A1 (enExample)
BR (1) BR112017000301A2 (enExample)
CA (1) CA2954522A1 (enExample)
EA (1) EA201790142A1 (enExample)
IL (1) IL249935A0 (enExample)
MX (1) MX2017000307A (enExample)
SG (1) SG11201700094TA (enExample)
WO (1) WO2016007423A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201735926A (zh) 2010-01-22 2017-10-16 艾斯特隆製藥公司 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
US10660890B2 (en) 2013-10-24 2020-05-26 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government Nih Division Of Extramural Inventions And Technology Resources (Deitr) Treatment of polycystic diseases with an HDAC6 inhibitor
US9949972B2 (en) 2013-12-03 2018-04-24 Acetylon Pharmaceuticals, Inc Combinations of histone deacetylase inhibitors and immunomodulatory drugs
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
ES2816641T3 (es) 2014-12-12 2021-04-05 Regenacy Pharmaceuticals Inc Derivados de piperidina en calidad de inhibidores de HDAC1/2
WO2016172734A1 (en) * 2015-04-24 2016-10-27 California Institute Of Technology Reactivation of x chromosome genes
TW201718516A (zh) 2015-06-08 2017-06-01 艾斯特隆製藥公司 組蛋白去乙醯酶抑制劑之晶形
TWI706937B (zh) 2015-06-08 2020-10-11 美商艾斯特隆製藥公司 製備蛋白質去乙醯酶抑制劑之方法
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
EP3468559B1 (en) 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
EP3532044A4 (en) 2016-10-27 2020-07-29 California Institute of Technology HDAC INHIBITOR COMPOSITIONS FOR CHROMOSOME X REACTIVATION
WO2018098168A1 (en) 2016-11-23 2018-05-31 Acetylon Pharmaceuticals, Inc. Pharmaceutical combinations comprising a histone deacetylase inhibitor and a programmed death-ligand 1 (pd-l1) inhibitor and methods of use thereof
CN106810460A (zh) * 2016-12-30 2017-06-09 苏州诚和医药化学有限公司 一种4‑[2‑(二甲基氨基)乙氧基]苄胺的制备方法
WO2019084434A1 (en) 2017-10-26 2019-05-02 National University Of Singapore NEW APPROACH FOR UNIVERSAL MONITORING OF MINIMUM RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA
JP7021503B2 (ja) * 2017-11-02 2022-02-17 三菱瓦斯化学株式会社 脂肪族ジアミンの製造方法
CN116421598B (zh) * 2022-01-11 2024-08-30 苏州亚盛药业有限公司 用于治疗aml-mrc和mds的方法
CN116966307A (zh) * 2022-04-22 2023-10-31 深圳先进技术研究院 Ampk抑制剂联合hdac抑制剂在制备肿瘤治疗的药物中的应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3549633A (en) 1968-11-20 1970-12-22 Merck & Co Inc Process for preparation of 1-h-imidazo (4,5-b)pyrazin-2-ones
US6777217B1 (en) 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
US20030129724A1 (en) 2000-03-03 2003-07-10 Grozinger Christina M. Class II human histone deacetylases, and uses related thereto
CA2404002A1 (en) 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
JPWO2002074298A1 (ja) 2001-03-21 2004-07-08 小野薬品工業株式会社 Ｉｌ−６産生阻害剤
US7244853B2 (en) 2001-05-09 2007-07-17 President And Fellows Of Harvard College Dioxanes and uses thereof
US7183288B2 (en) 2001-11-01 2007-02-27 Herwig Josephus Margareta Janssen, legal representative Amide derivatives as glycogen synthase kinase 3-β inhibitors
WO2003076400A1 (en) 2002-03-13 2003-09-18 Janssen Pharmaceutica N.V. New inhibitors of histone deacetylase
KR20040094672A (ko) 2002-03-13 2004-11-10 얀센 파마슈티카 엔.브이. 히스톤 디아세틸라제의 신규한 저해제로서의설포닐아미노-유도체
TWI319387B (en) 2002-04-05 2010-01-11 Astrazeneca Ab Benzamide derivatives
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
US7244751B2 (en) 2003-02-14 2007-07-17 Shenzhen Chipscreen Biosciences Ltd. Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
PT1651618E (pt) 2003-07-24 2007-03-30 Basf Ag Pirimidinas substituídas em 2
TWI349664B (en) 2003-09-22 2011-10-01 S Bio Pte Ltd Benzimidazole derivatives: preparation and pharmaceutical applications
EP1663953A1 (en) 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
US8227636B2 (en) 2004-04-05 2012-07-24 Merck Hdac Research, Llc Histone deacetylase inhibitor prodrugs
SG171690A1 (en) 2005-03-22 2011-06-29 Harvard College Treatment of protein degradation disorders
GB0510204D0 (en) 2005-05-19 2005-06-22 Chroma Therapeutics Ltd Enzyme inhibitors
WO2007022638A1 (en) 2005-08-26 2007-03-01 Methylgene Inc. Benzodiazepine and benzopiperazine analog inhibitors of histone deacetylase
US7928253B2 (en) 2005-11-01 2011-04-19 Sumitomo Chemical Company, Limited Method of producing 6,6-dimethyl-3-oxabicyclo[3.1.0]hexan-2-one
PT1981877E (pt) 2006-02-07 2012-05-24 Astellas Pharma Inc Compostos de n-hidroxiacrilamida
JP5441416B2 (ja) 2006-02-14 2014-03-12 プレジデント アンド フェロウズ オブ ハーバード カレッジ 二官能性ヒストンデアセチラーゼインヒビター
CA2648804C (en) 2006-04-07 2014-05-27 Methylgene Inc. Benzamide derivatives as inhibitors of histone deacetylase
EP2013196B1 (en) 2006-04-26 2015-09-16 Merck Sharp & Dohme Corp. Disubstituted aniline compounds
CA2654540C (en) 2006-05-03 2017-01-17 President And Fellows Of Harvard College Histone deacetylase and tubulin deacetylase inhibitors
WO2007144341A1 (en) 2006-06-12 2007-12-21 Vrije Universiteit Brussel Differentiation of rat liver epithelial cells into hepatocyte-like cells
ES2288802B1 (es) 2006-07-07 2008-12-16 Universidad De Granada Nuevos derivados de ftalimida como inhibidores de las histonas desacetilasas.
KR101433629B1 (ko) 2006-09-11 2014-08-27 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 티로신 키나아제 억제제
RU2459811C2 (ru) 2006-10-28 2012-08-27 Метилджен Инк. Ингибиторы гистоновой деацетилазы
MX2009004279A (es) 2006-10-30 2009-05-22 Chroma Therapeutics Ltd Hidroxamatos como inhibidores de histona desacetilasa.
WO2008102348A1 (en) 2007-02-21 2008-08-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Alpha-halo- and alpha-alkyl-cyclopropylcarboxy compounds and uses thereof
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
TW200924777A (en) 2007-09-14 2009-06-16 Methylgene Inc Combination therapy
CN101951930A (zh) 2008-02-19 2011-01-19 阿奈斯特药品株式会社 对身体功能的恢复有用的口服或经肠组合物
WO2009137462A2 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Methods for treating cognitive disorders using inhibitors of histone deacetylase
WO2009137503A1 (en) 2008-05-05 2009-11-12 Envivo Pharmaceuticals, Inc. Hdac inhibitors and uses thereof
AU2009271019A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
KR101708946B1 (ko) 2008-07-23 2017-02-21 다나-파버 캔서 인스티튜트 인크. 탈아세틸화제 억제제 및 그것의 용도
EA024252B1 (ru) 2009-01-08 2016-08-31 Кьюрис, Инк. Ингибиторы фосфоинозитид-3-киназ с цинксвязывающей группой
JP5713999B2 (ja) 2009-05-15 2015-05-07 コリア リサーチ インスティテュート オブ ケミカル テクノロジー アミド化合物、その製造方法及びそれを含む薬学組成物
CA2768466C (en) 2009-07-22 2018-08-14 The Board Of Trustees Of The University Of Illinois Hdac inhibitors and therapeutic methods using the same
WO2011019393A2 (en) 2009-08-11 2011-02-17 President And Fellows Of Harvard College Class- and isoform-specific hdac inhibitors and uses thereof
EP2638009A4 (en) 2010-01-08 2014-06-11 Harvard College FLUORINATED HDAC HEMMER AND USES THEREOF
TW201735926A (zh) 2010-01-22 2017-10-16 艾斯特隆製藥公司 作為蛋白質去乙醯酶抑制劑之反式醯胺化合物及其使用方法
EP2571352A4 (en) 2010-05-21 2014-09-17 Sloan Kettering Inst Cancer SELECTIVE HDAC HEMMER
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US8614223B2 (en) 2010-11-16 2013-12-24 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
US8404738B2 (en) 2011-01-21 2013-03-26 Hoffmann-La Roche Inc. 4-amino-N-hydroxy-benzamides for the treatment of cancer
EP2524918A1 (en) 2011-05-19 2012-11-21 Centro Nacional de Investigaciones Oncológicas (CNIO) Imidazopyrazines derivates as kinase inhibitors
US9512083B2 (en) * 2011-07-20 2016-12-06 The General Hospital Corporation Histone deacetylase 6 selective inhibitors for the treatment of bone disease
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) * 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US20140357512A1 (en) 2013-06-03 2014-12-04 Acetylon Pharmaceuticals, Inc. Histone deacetylase (hdac) biomarkers in multiple myeloma
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
WO2015054474A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
KR20160060143A (ko) 2013-10-11 2016-05-27 에이스틸론 파마수티컬스 인코포레이티드 히스톤 디아세틸라아제 억제제와 면역조절성 약물의 조합물
US9949972B2 (en) 2013-12-03 2018-04-24 Acetylon Pharmaceuticals, Inc Combinations of histone deacetylase inhibitors and immunomodulatory drugs
EP3084446B1 (en) 2013-12-20 2022-12-14 Acetylon Pharmaceuticals, Inc. Histone deacetylase 6 (hdac6) biomarkers in multiple myeloma
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors

Also Published As

Publication number Publication date
BR112017000301A2 (pt) 2017-11-07
EP3166603B1 (en) 2020-02-12
MX2017000307A (es) 2017-11-23
AU2015288060A1 (en) 2017-02-09
WO2016007423A1 (en) 2016-01-14
EP3166603A4 (en) 2017-12-13
SG11201700094TA (en) 2017-02-27
US9833466B2 (en) 2017-12-05
IL249935A0 (en) 2017-03-30
EP3166603A1 (en) 2017-05-17
CA2954522A1 (en) 2016-01-14
JP6952602B2 (ja) 2021-10-20
CN107205988A (zh) 2017-09-26
KR20170044097A (ko) 2017-04-24
US20160030458A1 (en) 2016-02-04
JP2017524735A (ja) 2017-08-31

Similar Documents

Publication Publication Date Title
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
CY1122186T1 (el) Μεθοδοι θεραπειας καρκινου
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
ZA202208792B (en) Methods of treating and preventing graft versus host disease
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201691155A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201790398A1 (ru) Способы лечения заболевания печени
MX384792B (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
EA201790576A1 (ru) Спироциклические ингибиторы катепсина с
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890754A1 (ru) Соединения и способы их применения
EA201591509A1 (ru) Ингибиторы cdc7
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791095A1 (ru) Способ лечения рака
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
MX382162B (es) Combinaciones farmacéuticas de un inhibidor de enzima hdac con un inhibidor de proteasoma, y su uso en el tratamiento de cáncer.
EA201690039A1 (ru) Ингибиторы rorc2 и способы их применения
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201491500A1 (ru) Способы лечения фиброза
EA201791933A1 (ru) Ингибирование активности olig2
EA201690561A1 (ru) Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i
EA201691896A1 (ru) Соединения и способы их применения